Durvalumab and Oleclumab in Resectable PDAC

Sponsor
University Health Network, Toronto
Study ID
NCT06060405
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
  • Oleclumab — DRUG
    Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.

Study Details

This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.

Key Dates

Start date
Nov 29, 2023
Status verified
Jan 2024
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026

Study Design

Enrollment
22 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab and Oleclumab
    Durvalumab, 1500 mg x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to surgical resection.

Primary Outcome Measure

Percent change in CD8+ cell infiltration [ Time Frame: Baseline biopsy to surgical resection (35 days) ]

Central Contacts

Related Studies